171 related articles for article (PubMed ID: 37448247)
1. [Alemtuzumab-induced Graves' disease].
Sheremeta MS; Korchagina MO; Guseinova RM; Schmidt TE; Nizhegorodova KS; Sviridenko NY; Melnichenko GA
Probl Endokrinol (Mosk); 2023 Jun; 69(3):51-57. PubMed ID: 37448247
[TBL] [Abstract][Full Text] [Related]
2. Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves' orbitopathy: a case series.
Roos JCP; Moran C; Chatterjee VK; Jones J; Coles A; Murthy R
Eye (Lond); 2019 Feb; 33(2):223-229. PubMed ID: 30498266
[TBL] [Abstract][Full Text] [Related]
3. Prevalence, Risk Factors, and Clinical and Biochemical Characteristics of Alemtuzumab-Induced Graves Disease.
Ueland GÅ; Ueland HO; Stokland AM; Bhan A; Schønberg A; Sollid ST; Morgas DE; Holmøy T; Lima K; Methlie P; Løvås K; Torkildsen Ø; Husebye ES
J Clin Endocrinol Metab; 2024 Jan; 109(2):344-350. PubMed ID: 37708353
[TBL] [Abstract][Full Text] [Related]
4. Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study.
Kazakou P; Tzanetakos D; Vakrakou AG; Tzartos JS; Evangelopoulos ΜE; Anagnostouli M; Stathopoulos P; Kassi GN; Stefanis L; Kilidireas C; Zapanti E
Clin Exp Med; 2023 Oct; 23(6):2885-2894. PubMed ID: 36641771
[TBL] [Abstract][Full Text] [Related]
5. Onset of Marine-Lenhart syndrome and Graves' ophthalmopathy in a female patient treated with alemtuzumab for multiple sclerosis.
Le Moli R; Russo M; Malandrino P; Vella V; Belfiore A; Frasca F
Hormones (Athens); 2021 Mar; 20(1):161-165. PubMed ID: 32500462
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab-induced thyroid eye disease successfully treated with a single low dose of rituximab.
Muller I; Maioli S; Armenti M; Porcaro L; Currò N; Iofrida E; Pignataro L; Manso J; Mian C; Geginat J; Salvi M
Eur Thyroid J; 2024 Apr; 13(2):. PubMed ID: 38471303
[TBL] [Abstract][Full Text] [Related]
7. Graves' disease after treatment with alemtuzumab for multiple sclerosis.
Tsourdi E; Gruber M; Rauner M; Blankenburg J; Ziemssen T; Hofbauer LC
Hormones (Athens); 2015; 14(1):148-53. PubMed ID: 25402383
[TBL] [Abstract][Full Text] [Related]
8. Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis.
Alamo A; Condorelli RA; La Vignera S; Calogero AE
Int J Immunopathol Pharmacol; 2019; 33():2058738419843690. PubMed ID: 30968726
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab-induced autoimmune thyroid events in patients with relapsing-remitting multiple sclerosis: A real-life and monocentric experience at a tertiary-level centre.
Manso J; Zhu YH; Margoni M; Rinaldi F; Censi S; Carducci S; Cosma C; Plebani M; Gallo P; Mian C
Clin Endocrinol (Oxf); 2022 Sep; 97(3):331-338. PubMed ID: 34724236
[TBL] [Abstract][Full Text] [Related]
10. Graves' disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis.
Duarte DB; Silva AMD; Freitas C; Cardoso H
Endocr Regul; 2021 Sep; 55(3):169-173. PubMed ID: 34523298
[No Abstract] [Full Text] [Related]
11. Graves' disease induced by Alemtuzumab in relapsing-remitting multiple sclerosis patients: an observational study in a reference center.
Rodríguez de Vera Gómez P; García-González JJ; Ravé-García R; López Ruiz R; Torres-Cuadro A; Eichau-Madueño S; García-García C; Martín-Hernández T
J Endocrinol Invest; 2022 Oct; 45(10):1977-1990. PubMed ID: 35718853
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSH-Receptor Immune Response.
Rotondi M; Molteni M; Leporati P; Capelli V; Marinò M; Chiovato L
Front Endocrinol (Lausanne); 2017; 8():254. PubMed ID: 29033895
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis.
Scappaticcio L; Castellana M; Virili C; Bellastella G; Centanni M; Cannavò S; Campennì A; Ruggeri RM; Giovanella L; Trimboli P
J Endocrinol Invest; 2020 Feb; 43(2):219-229. PubMed ID: 31452116
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features.
Pariani N; Willis M; Muller I; Healy S; Nasser T; McGowan A; Lyons G; Jones J; Chatterjee K; Dayan C; Robertson N; Coles A; Moran C
J Clin Endocrinol Metab; 2018 Aug; 103(8):3010-3018. PubMed ID: 29878256
[TBL] [Abstract][Full Text] [Related]
15. Development of Autoimmune Thyroid Disease in Multiple Sclerosis Patients Post-Alemtuzumab Improves Treatment Response.
Sovetkina A; Nadir R; Scalfari A; Tona F; Murphy K; Rigoni E; Dorsey R; Malik O; Nandoskar A; Singh-Curry V; Nicholas R; Martin N
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32667988
[TBL] [Abstract][Full Text] [Related]
16. Thyroid Storm in a Patient With Alemtuzumab-Induced Graves' Disease: A Case Report.
AlShehri S; Alajmi S; Ekhzaimy A; Aldawas S; Alalwan M
Cureus; 2022 Apr; 14(4):e24570. PubMed ID: 35651398
[TBL] [Abstract][Full Text] [Related]
17. Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: a review.
Aranha AA; Amer S; Reda ES; Broadley SA; Davoren PM
Endocr Pract; 2013; 19(5):821-8. PubMed ID: 23757618
[TBL] [Abstract][Full Text] [Related]
18. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
19. [Thyrotoxicosis in a patient with Turner syndrome: radioactive iodine therapy].
Guseinova RM; Prosvirnina AA; Korchagina MO; Trukhin AA; Sheremeta MS
Probl Endokrinol (Mosk); 2022 Jul; 68(6):49-58. PubMed ID: 36689711
[TBL] [Abstract][Full Text] [Related]
20. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.
Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri
J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
